Source Count: 15 | Weighted Score: 37 | Source Confidence: [4/5] | Primary Tier: 1–2 | Last Updated: April 12, 2026
Keywords: longevity, senolytics, senescence, aging, rapamycin, mTOR, telomere, caloric restriction, NAD+, Yamanaka factors, rejuvenation, geroscience, healthspan, dasatinib, quercetin
Category Tags: longevity, geroscience, aging, biotechnology, senolytics
Cross-References: ZB_2_19 — Epigenetics · R_3_20 — CRISPR Gene Editing · X_1_01 — Medicine Overview

QUICK SUMMARY

Longevity science — also termed geroscience — aims to understand and intervene in the biological mechanisms of aging to extend human healthspan (years of healthy life) and potentially lifespan. The field has shifted from viewing aging as an intractable process to treating it as a modifiable biological condition with specific molecular drivers. Nine "hallmarks of aging" were formalized by Carlos López-Otín, Maria Blasco, Linda Partridge, Manuel Serrano, and Guido Kroemer in a landmark 2013 Cell paper (updated to 12 hallmarks in 2023): genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication (plus dysbiosis, chronic inflammation, and disabled macroautophagy in the 2023 update). The most promising interventions include: senolytics — drugs that selectively kill senescent cells (pioneered by James Kirkland at Mayo Clinic, who demonstrated that dasatinib + quercetin extends healthspan in aged mice by 36%, published 2015); rapamycin/mTOR inhibition (the only pharmacological intervention that robustly extends lifespan across yeast, worms, flies, and mice, by ~10–25%); NAD+ precursors (nicotinamide riboside, NMN) targeting mitochondrial decline; caloric restriction (the oldest known lifespan-extending intervention, demonstrated in rodents since the 1930s by Clive McCay); and partial cellular reprogramming using Yamanaka factors (OSKM), which Alejandro Ocampo and Juan Carlos Izpisúa Belmonte (Salk Institute, 2016) showed can reverse age-associated epigenetic markers in mice without dedifferentiation. The field faces the challenge that no intervention has yet been proven to extend healthy human lifespan in a randomized controlled trial.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Established)

1.1 Hallmarks of Aging

• KEY FINDING The 2013 López-Otín et al. framework organized aging biology into nine interconnected hallmarks, each satisfying three criteria: manifests during normal aging, experimental aggravation accelerates aging, experimental amelioration retards aging. The 2023 update added three additional hallmarks (chronic inflammation [inflammaging], dysbiosis, and disabled macroautophagy) and refined the classification into primary hallmarks (causes of damage), antagonistic hallmarks (responses to damage), and integrative hallmarks (culprits of the phenotype). This framework unified decades of disparate aging research and provided a systematic target map for interventions.
• Primary Source: López-Otín, Carlos, et al. "Hallmarks of aging: An expanding universe." Cell 186.2 (2023): 243–278. DOI: 10.1016/j.cell.2022.11.001

1.2 Caloric Restriction and the CALERIE Trial

• Evidence: Caloric restriction (CR, typically 20–40% reduction without malnutrition) extends lifespan by 30–50% in rodents (first demonstrated by Clive McCay, Cornell, 1935) and by ~10% in rhesus monkeys (Wisconsin study: Richard Weindruch et al., 2009; NIA study: Rafael de Cabo et al., 2012 — results differed partly due to control diet composition). The CALERIE (Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy) trial — the first randomized controlled trial of CR in healthy non-obese humans (218 participants, 2 years, 12% actual CR achieved) — reported reduced cardiometabolic risk factors, decreased inflammatory markers, improved thymic function (CALERIE-2, Vishwa Deep Dixit et al., Science, 2022), and epigenetic age deceleration of ~2–3 years. CR activates conserved nutrient-sensing pathways: AMPK, sirtuins (SIRT1–7), and inhibits mTOR.
• Primary Source: Ravussin, Eric, et al. "A 2-Year Randomized Controlled Trial of Human Caloric Restriction." Journal of Gerontology: Medical Sciences 70.9 (2015): 1097–1104. DOI: 10.1093/gerona/glv057

1.3 Senolytics: Targeting Cellular Senescence

• KEY FINDING Cellular senescence — the irreversible growth arrest of damaged cells, accompanied by the senescence-associated secretory phenotype (SASP: pro-inflammatory cytokines, growth factors, proteases) — accumulates with age and drives tissue dysfunction. Jan van Deursen (Mayo Clinic, 2011) demonstrated that selective elimination of p16Ink4a-positive senescent cells in BubR1 progeroid mice delayed age-related pathologies. James Kirkland and Tamara Tchkonia (Mayo Clinic, 2015) identified the first senolytic drug combination: dasatinib (a tyrosine kinase inhibitor) + quercetin (a flavonoid) selectively killed senescent cells by targeting pro-survival pathways (BCL-2/BCL-xL, PI3K, p53). In aged mice, D+Q treatment extended healthspan by 36%, improved cardiovascular function, and reduced frailty. First human senolytic trial results (2019, idiopathic pulmonary fibrosis patients, 14 participants): D+Q improved 6-minute walk distance and other physical measures. Larger Phase 2 trials are ongoing.
• Primary Source: Zhu, Yi, et al. "The Achilles' heel of senescent cells: from transcriptome to senolytic drugs." Aging Cell 14.4 (2015): 644–658. DOI: 10.1111/acel.12344

1.4 Rapamycin and mTOR Pathway

• Evidence: Rapamycin — an mTOR (mechanistic target of rapamycin) inhibitor originally discovered as an antifungal from Easter Island soil bacteria (1972, Suren Sehgal) — is the most robust pharmacological lifespan-extending compound known. The NIA Interventions Testing Program (ITP) demonstrated that rapamycin extends median lifespan in genetically heterogeneous mice by 9–14% even when treatment begins at 20 months of age (equivalent to ~60 human years), published by David Harrison et al. (Nature, 2009). mTOR integrates nutrient and growth factor signals to regulate protein synthesis, autophagy, and metabolism; its inhibition mimics caloric restriction at the molecular level. Human applications are complicated by rapamycin's immunosuppressive properties (it is FDA-approved to prevent organ transplant rejection), though low-dose intermittent protocols are under investigation for aging (PEARL, AgelessRx trials).
• Primary Source: Harrison, David, et al. "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice." Nature 460.7253 (2009): 392–395. DOI: 10.1038/nature08221

2. CREDIBLE CLAIMS (Tier 2 — Academic / Debated but Supported)

2.1 Partial Reprogramming with Yamanaka Factors

• Evidence: Shinya Yamanaka (Kyoto University, Nobel Prize 2012) discovered that four transcription factors (Oct4, Sox2, Klf4, c-Myc — OSKM) reprogram differentiated adult cells into induced pluripotent stem cells (iPSCs). Alejandro Ocampo et al. (Salk Institute, 2016) showed that cyclic, short-duration expression of OSKM in progeroid mice reversed multiple hallmarks of aging (epigenetic dysregulation, mitochondrial dysfunction, cellular senescence) without causing teratomas or dedifferentiation — extending lifespan by ~33%. David Sinclair (Harvard, 2023) demonstrated that adeno-associated virus (AAV)-delivered OSK (without c-Myc, an oncogene) restored youthful gene expression patterns in aged mouse retinal ganglion cells, reversing vision loss. Human translation faces major challenges: delivery method, tumor risk from pluripotency factors, dosing precision, and tissue-specific targeting.

2.2 NAD+ Decline and Supplementation

• Evidence: Nicotinamide adenine dinucleotide (NAD+) — an essential coenzyme for mitochondrial metabolism, DNA repair (PARP enzymes), and sirtuin activity — declines ~50% between ages 25 and 65 in human tissues. David Sinclair and Leonard Guarente have promoted NAD+ precursors (nicotinamide riboside [NR] and nicotinamide mononucleotide [NMN]) as anti-aging supplements. Mouse published findings demonstrate NMN improves vascular function, insulin sensitivity, and mitochondrial function in aged animals. However, human RCTs have shown modest results: the NRTC trial (2022) found NR improved NAD+ levels but did not significantly change physical performance or cardiometabolic markers in older adults over 3 months. Whether NAD+ supplementation produces meaningful healthspan extension in humans remains unproven.

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

3.1 Longevity Escape Velocity

• Evidence: Aubrey de Grey (SENS Research Foundation) proposed "longevity escape velocity" (LEV): the point at which medical advances extend remaining life expectancy faster than time passes — effectively making aging-related death optional. de Grey initially estimated LEV could be reached by the 2030s–2040s, contingent on adequate research funding. The concept requires that therapies for each hallmark of aging compound multiplicatively (addressing senescence + telomere maintenance + proteostasis + etc. = radically extended lifespan). Most gerontologists consider LEV speculative: individual interventions produce diminishing returns, and the interaction between hallmarks may limit compounding effects. No organism has achieved indefinite lifespan through intervention.

3.2 Heterochronic Parabiosis and Young Blood

• Evidence: Irina Conboy and Michael Conboy (UC Berkeley, 2005) revived 19th-century parabiosis experiments by surgically joining old and young mice, demonstrating that old mice showed improved muscle regeneration, liver function, and neurogenesis when sharing circulatory systems with young mice. Conversely, young mice showed accelerated aging. This suggested that circulating factors in young blood rejuvenate tissues while old blood contains pro-aging factors. Tony Wyss-Coray (Stanford, 2014) showed that young mouse plasma alone (without surgical parabiosis) improved memory and neuroplasticity in old mice. The specific factors responsible remain debated (GDF11 was proposed but contested; TIMP2, oxytocin, and dilution of aged plasma have been implicated). The human "young blood" commercial services (Ambrosia) lack clinical evidence.

4. DUBIOUS CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

4.1 Current Supplements Achieve Radical Life Extension

• DEBUNKED No currently available supplement (resveratrol, NMN, NR, metformin, spermidine, etc.) has been demonstrated to extend human lifespan in randomized controlled trials. The supplement industry markets anti-aging claims based on mouse data, mechanistic plausibility, and biomarker surrogates without clinical outcome evidence. GlaxoSmithKline's $720 million acquisition of Sirtris Pharmaceuticals (resveratrol/SIRT1 activators, 2008) yielded no approved anti-aging drug before the program was shut down in 2013.

Counter-Arguments & Criticisms

Longevity science faces ethical, practical, and scientific objections. Daniel Callahan (Hastings Center) and Leon Kass argue that radical life extension would disrupt social structures (career cycles, generational turnover, resource allocation), exacerbate inequality (only the wealthy would access therapies initially), and potentially diminish life's meaning (mortality as motivation). Practically, the translation gap between mice and humans is enormous: mouse lifespan studies take 2–3 years; equivalent human trials would require decades. The geroscience hypothesis — that targeting aging's root mechanisms will simultaneously prevent multiple age-related diseases — is attractive but unproven; diseases may have pathologies independent of aging hallmarks. Rapamycin's immunosuppression, Yamanaka factors' teratoma risk, and senolytics' potential to impair wound healing illustrate that anti-aging interventions carry significant side effects. S. Jay Olshansky (University of Illinois at Chicago) has consistently argued that modest healthspan gains (2–7 years) are achievable but radical life extension (centuries) is biologically implausible given the complexity of aging.

IMAGES

No images assigned yet.

BIBLIOGRAPHY

1. López-Otín, Carlos, et al | 2023 | "Hallmarks of aging: An expanding universe" | Cell | ∅ | 186.2::243–278 | ∅ | ∅ | doi:10.1016/j.cell.2022.11.001 | ∅ | ∅ | ∅
2. Zhu, Yi, et al | 2015 | "The Achilles' heel of senescent cells: from transcriptome to senolytic drugs" | Aging Cell | ∅ | 14.4::644–658 | ∅ | ∅ | doi:10.1111/acel.12344 | ∅ | ∅ | ∅
3. Harrison, David, et al | 2009 | "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice" | Nature | ∅ | 460.7253::392–395 | ∅ | ∅ | doi:10.1038/nature08221 | ∅ | ∅ | ∅
4. Ocampo, Alejandro, et al | 2016 | "In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming" | Cell | ∅ | 167.7::1719–1733 | ∅ | ∅ | doi:10.1016/j.cell.2016.11.052 | ∅ | ∅ | ∅
5. van Deursen, Jan | 2014 | "The role of senescent cells in ageing" | Nature | ∅ | 509.7501::439–446 | ∅ | ∅ | doi:10.1038/nature13193 | ∅ | ∅ | ∅
6. Ravussin, Eric, et al | 2015 | "A 2-Year Randomized Controlled Trial of Human Caloric Restriction" | Journal of Gerontology: Medical Sciences | ∅ | 70.9::1097–1104 | ∅ | ∅ | doi:10.1093/gerona/glv057 | ∅ | ∅ | ∅
7. Conboy, Irina, et al | 2005 | "Rejuvenation of aged progenitor cells by exposure to a young systemic environment" | Nature | ∅ | 433.7027::760–764 | ∅ | ∅ | doi:10.1038/nature03260 | ∅ | ∅ | ∅
8. Villeda, Saul, et al | 2014 | "Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice" | Nature Medicine | ∅ | 20.6::659–663 | ∅ | ∅ | doi:10.1038/nm.3569 | ∅ | ∅ | ∅
9. Mattison, Julie, et al | 2012 | "Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study" | Nature | ∅ | 489.7415::318–321 | ∅ | ∅ | doi:10.1038/nature11432 | ∅ | ∅ | ∅
10. Sinclair, David; Matthew LaPlante | 2019 | ∅ | Lifespan: Why We Age — and Why We Don't Have To | ∅ | ∅ | New York: Atria Books | ∅ | isbn:9781501191902 | ∅ | ∅ | ∅
11. Baker, Darren, et al | 2011 | "Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders" | Nature | ∅ | 479.7372::232–236 | ∅ | ∅ | doi:10.1038/nature10600 | ∅ | ∅ | ∅
12. de Grey, Aubrey; Michael Rae | 2007 | ∅ | Ending Aging: The Rejuvenation Breakthroughs That Could Reverse Human Aging in Our Lifetime | ∅ | ∅ | New York: St | ∅ | isbn:9780312367060 | ∅ | ∅ | Martin's
13. Kennedy, Brian, et al | 2014 | "Geroscience: Linking Aging to Chronic Disease" | Cell | ∅ | 159.4::709–713 | ∅ | ∅ | doi:10.1016/j.cell.2014.10.039 | ∅ | ∅ | ∅
14. Olshansky, S | 2018 | "From Lifespan to Healthspan" | JAMA | ∅ | 320.13::1323–1324 | Jay | ∅ | doi:10.1001/jama.2018.12621 | ∅ | ∅ | ∅
15. Dixit, Vishwa Deep, et al | 2022 | "Caloric restriction in humans reveals immunometabolic regulators of health span" | Science | ∅ | 375.6581::671–677 | ∅ | ∅ | doi:10.1126/science.abg7292 | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

Generated from V4 expansion plan. Last Updated: April 12, 2026